GMCM
AZN icon

Gruber & McBaine Capital Management’s AstraZeneca AZN Stock Holding History

Gruber & McBaine Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-30,000
Closed -$1.95M – 204
2014
Q1 		$1.95M Hold
30,000
– – 0.51% 62
2013
Q4 		$1.78M Buy
+30,000
New +$1.63M 0.46% 67

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
MCM
Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Gruber & McBaine Capital Management's AZN Position: Q2 2014 in Review

Gruber & McBaine Capital Management sold out of AstraZeneca (AZN) in Q2 2014, closing a stake of 30,000 shares — an estimated $1.95M sold.

Gruber & McBaine Capital Management first reported a position in AZN in Q4 2013 and held it in 2 quarters. The position peaked at $1.95M in Q1 2014. 419 funds tracked by Wall St. Rank hold AZN as of Q2 2014.

  • Gruber & McBaine Capital Management reported no remaining AstraZeneca position as of Q2 2014 after selling out during the quarter.
  • Gruber & McBaine Capital Management sold 30,000 AstraZeneca shares in Q2 2014, an estimated $1.95M.
  • Gruber & McBaine Capital Management first reported a position in AstraZeneca in Q4 2013 and held it in 2 quarters.
  • Gruber & McBaine Capital Management's AstraZeneca position peaked at $1.95M in Q1 2014.
  • 419 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2014.

Based on Gruber & McBaine Capital Management's 13F filing for Q2 2014, filed 13 Aug 2014.